Therapy Areas: Respiratory
Akron Biotech Signs Agreement with Synairgen plc to Supply Interferon-beta for COVID-19 Treatment
19 October 2020 - - US-based cell- and protein-based therapies developer Akron biotechnology has signed an agreement with UK-based respiratory drug discovery and development company Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgen's wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients, the company said.

Akron Biotech provides cGMP-compliant solutions to support the development and commercialization of advanced therapies.

Synairgen reported positive results from its Phase II trial of SNG001 in 101 hospitalized COVID-19 patients in July 2020, indicating that its inhaled IFN-beta could provide a valuable treatment option in the face of the global COVID-19 pandemic.

Furthermore, the safety, biomarker, and efficacy data for SNG001 provided from the interim analysis of Synairgen's Phase II COPD trial in September 2020 was supportive of the on-going development of SNG001 in COVID-19 patients.

Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgen's formulation.

Akron is a provider of cGMP-compliant solutions to support the development of novel cell- and protein-based therapies.

An ISO 13485-certified company operating in line with cGMP guidelines and international standards, Akron leverages more than 100,000 square feet of development and manufacturing capacity to provide therapy developers the scale, compliance, and regulatory support necessary to drive novel treatments from discovery to commercialization.

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic.

The business, focused primarily on lung viral defense in asthma, COPD, and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is quoted on AIM (LSE: SNG).
Login
Username:

Password: